Psilocybin-Assisted Therapy Shows Promise in Small Fibromyalgia Trial
核心洞察
A pilot clinical trial demonstrates psilocybin-assisted therapy's safety profile in fibromyalgia (搜索) patients, with only minor transient side effects including headaches and temporary blood pressure elevations.
Participants reported significant improvements in key symptoms, with pain severity reduction (d=-2.1), decreased pain interference (d=-1.8), and improved sleep quality (d=-2.5) one month after treatment.
Three out of five participants reported their symptoms as "much improved" or "very much improved" following two doses of psilocybin combined with psychotherapy sessions.
In a groundbreaking pilot study, researchers have found preliminary evidence supporting the safety and potential effectiveness of psilocybin-assisted therapy (PAT) for treating fibromyalgia (搜索), a challenging chronic pain condition that has limited treatment options.
The open-label clinical trial, though small with five participants, marks the first investigation of PAT specifically for fibromyalgia (搜索) patients. The treatment protocol combined psychotherapy with two oral doses of psilocybin (15mg and 25mg) administered two weeks apart, accompanied by two preparatory and four integration therapy sessions.
Safety Profile and Tolerability
The study's primary outcome focused on safety parameters, revealing a manageable side effect profile. Participants experienced temporary elevations in blood pressure and heart rate during dosing sessions, which normalized by the end of treatment. Four of the five participants reported transient headaches following psilocybin administration, but notably, no serious adverse events were documented.
Significant Symptom Improvements
The treatment showed promising results across several key metrics one month after the second psilocybin dose. Statistical analysis revealed substantial improvements in:
- Pain severity (Cohen's d=-2.1, 95% CI[-3.7 to -0.49])
- Pain interference with daily activities (d=-1.8, 95% CI [-3.27 to -0.24])
- Sleep disturbance (d=-2.5, 95% CI [-4.21 to -0.75])
Patient-reported outcomes were particularly encouraging, with one participant reporting their symptoms as "very much improved," two noting they were "much improved," and two indicating "minimally improved" on the Patient Global Impression of Change scale.
Study Limitations and Future Directions
While the trial was initially designed for a larger cohort, recruitment was halted early due to concerns about result generalizability and changes in FDA guidance regarding psychedelic clinical trials. Despite these limitations, the researchers note that these preliminary findings establish a foundation for larger, randomized controlled trials to further investigate PAT's potential in fibromyalgia (搜索) treatment.
The results are particularly significant given fibromyalgia (搜索)'s classification as a nociplastic pain condition, characterized by widespread pain accompanied by cognitive difficulties, mood disorders, and sleep disturbances. With current treatment options often providing limited relief, these findings suggest a potentially promising new therapeutic approach for this challenging condition.